Advice

Following a full submission:

risankizumab (Skyrizi®) is accepted for restricted use within NHSScotland.

Indication under review: for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

SMC restriction: for patients who have failed to respond to conventional systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contraindication to these treatments.

Risankizumab was superior to placebo, a tumour necrosis factor antagonist, and an interleukin 12/23 antagonist in improving symptoms of adult patients with moderate to severe plaque psoriasis.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of risankizumab. This SMC advice is contingent upon the continuing availability of the patient access scheme, or a list price that is equivalent or lower, in NHSScotland.

Medicine details

Medicine name:
risankizumab (Skyrizi)
SMC ID:
SMC2196
Indication:

For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Pharmaceutical company
AbbVie Ltd
BNF chapter
Skin
Submission type
Full
Status
Restricted
Date advice published:
07 October 2019